Elicio Therapeutics, Inc. (ELTX)
| Previous Close | 4.7600 |
| Open | 4.8400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 4.6000 - 4.9250 |
| 52 Week Range | 2.9600 - 11.4500 |
| Volume | |
| Avg. Volume | 14,376 |
| Market Cap | 50.371M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 5.08 |
| EPS (TTM) | 0.9200 |
| Earnings Date | Nov 07, 2024 - Nov 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.50 |
GlobeNewswireElicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
Poster presentation at SITC to highlight extended follow-up data from AMPLIFY-7P Phase 1 study Oral presentation at SU2C Innovation Summit to highlight data from AMPLIFY-7P and AMPLIFY-201 Phase 1 studies BOSTON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced two upcoming presentations in November. The f
ZacksAll You Need to Know About Elicio Therapeutics (ELTX) Rating Upgrade to Strong Buy
Elicio Therapeutics (ELTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GlobeNewswire
Elicio Therapeutics Reports Inducement Grants
BOSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on October 15, 2024, Elicio granted an aggregate of 5,900 inducement stock options to two new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The ind
